TICKERNERD
Menu
OSUROSURHealthcare · Medical Instruments & Supplies

OSUR Stock Forecast: OraSure Technologies, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$3.72
+5.38% on the day

The 2 Wall Street analysts covering OraSure Technologies, Inc. hold a median 12-month price target of $5.5 — +47.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$256.6M
Ticker Nerd rank
77/ 100
Median analyst target
$5.50
Analysts covering
2
Revenue$30.6M−1.9% y/y
Operating income−$17.2M
Net income$6.2M
Free cash flow−$12.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.3%
1M
−6.3%
YTD
+53.7%
1Y
+44.7%
From 52W high
−17.3%
From 52W low
+76.3%
$2.11
$4.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OSUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OraSure Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
77/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
76
Momentum
76
Issuance
73
Accruals
66
Revisions
64
Size
63
Volatility
59
Value
52
Quality
27

Growth (76): Sales and profits are climbing, and climbing faster than before.

Quality (27): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OSUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OSUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26OSURHigh $7.00Median $5.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $4.00Median $5.50High $7.00

The green dot is the last close — the median target sits +47.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Nov 2025Stephens & Co.MaintainsEqual-Weight$3.50 → $3.00
19 May 2025Evercore ISI GroupMaintainsIn-Line—
8 May 2025Evercore ISI GroupMaintainsIn-Line—
7 Aug 2024Evercore ISI GroupMaintainsIn-Line—
2 July 2024Evercore ISI GroupMaintainsIn-Line—
13 May 2024JP MorganMaintainsNeutral—
4 Apr 2024Evercore ISI GroupMaintainsIn-Line—
29 Feb 2024JP MorganMaintainsNeutral—
11 Dec 2023CitigroupMaintainsBuy—
8 Nov 2023JP MorganMaintainsNeutral—
17 July 2023Stephens & Co.MaintainsEqual-Weight—
11 May 2022CitigroupMaintainsBuy—
24 Feb 2022CitigroupMaintainsBuy—
22 Sept 2021Raymond JamesDowngradeMarket Perform—
4 Aug 2021Raymond JamesMaintainsOutperform—
28 June 2021Raymond JamesMaintainsOutperform—
6 May 2021Raymond JamesMaintainsOutperform—
21 Aug 2020Evercore ISI GroupInitiatesOutperform—
10 Aug 2020CitigroupInitiatesBuy—
10 Aug 2020JP MorganInitiatesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

OSUR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OSUR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, OraSure Technologies, Inc. returned +44.7% against +12.9% for the S&P 500, dividends included.

OSUR vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26OSURS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OSUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

OraSure Technologies, Inc. (OSUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.9×

Cheaper than 38% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
−1.5×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−1.9%

Higher than 25% of US stocks

Earnings growth (YoY)
—
Gross margin
43.5%

Higher than 54% of US stocks

Operating margin
−56.0%

Higher than 16% of US stocks

Net margin
−43.7%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−14.1%

Higher than 34% of US stocks

Return on assets
−11.0%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

OraSure Technologies, Inc. (OSUR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • OraSure Technologies, Inc. has a market value of $256.6M and an enterprise value of $95.0M.

  • Revenue in the twelve months to 30 June 2026: $112.4M. The latest quarter shrank 1.9% year on year.

  • Net income over the same four quarters: −$49.1M, a −43.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.69.

  • Free cash flow in the twelve months to 30 June 2026: −$48.1M.

  • OraSure Technologies, Inc. spent $18.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 69.0M.

  • Trailing P/E: 19.9×; forward P/E: −5.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • OraSure Technologies, Inc. employs 500 people — $225K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

OSUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
OSUROraSure Technologies, Inc.$256.6M77
UTMDUtah Medical Products, Inc.$222.9M77
SMTISanara MedTech, Inc.$295.6M91
PDEXPro-Dex, Inc.$192.3M95
EMBCEmbecta Corp.$360.1M88
KRMDKORU Medical Systems, Inc.$142.4M95
ZJYLJin Medical International Ltd.$430.3M14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OraSure Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OSUR news & analysis

OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care

GlobeNewsWire · 2 Nov 2026positive

OraSure Technologies joined the World Coalition on Sickle Cell Disease. The collaboration will contribute diagnostics expertise to a global, multi-stakeholder effort focused on policy, advocacy, and practical implementation.

Why it matters — OSUR watchers may note the company’s participation in an effort to advance earlier diagnosis and care for people with sickle cell disease.

OraSure Technologies, Inc. (OSUR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of OraSure Technologies' (OSUR) Q2 2026 earnings call, based on the company's recent earnings event. The excerpt offers the headline and source only, with no additional details on results.

Why it matters — An OSUR watcher would care because the transcript gives access to management's commentary on the company's second-quarter 2026 performance.

OraSure Technologies Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

OraSure Technologies reported second-quarter revenue of $30.6 million, surpassing its guidance range and growing 9.7% sequentially. The company attributed the results to stronger public-health diagnostics demand and growth in its sample-management products.

Why it matters — OSUR watchers would care because the company beat its own revenue guidance on sequential growth in two key product areas.

OraSure Announces Second Quarter 2026 Financial Results

GlobeNewsWire · 5 Aug 2026neutral

OraSure Technologies announced its financial results for the three months ended June 30, 2026 (second quarter 2026), via a press release issued on August 5, 2026, out of its Bethlehem, Pennsylvania headquarters.

Why it matters — OSUR watchers would look to this announcement for the company's official quarterly financial performance disclosure for the period.

FAQ

Frequently asked questions about OSUR stock

What is the OSUR stock price forecast for 2026-2027?

The 2 Wall Street analysts covering OraSure Technologies, Inc. have a median 12-month price target of $5.5, with estimates ranging from $4 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OSUR stock a buy right now?

Of the 2 analysts covering OraSure Technologies, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OraSure Technologies, Inc. 77 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OSUR?

As at 3 Nov 2026, OraSure Technologies, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (76 of 100).

Will OSUR stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +47.8% from the last close, and Ticker Nerd's factor model ranks OraSure Technologies, Inc. 77 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OSUR stock forecast for 2030?

No analyst covering OraSure Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSUR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $7 over the next 12 months.

How has OSUR stock performed over the past year?

OraSure Technologies, Inc. returned +44.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OraSure Technologies, Inc. do?

OraSure Technologies Inc. is a medical diagnostics and sample management company focused on point-of-need and home testing solutions.

What is the latest news on OSUR?

The most recent item we track (GlobeNewsWire, 2 Nov 2026): "OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care". OraSure Technologies joined the World Coalition on Sickle Cell Disease. The collaboration will contribute diagnostics expertise to a global, multi-stakeholder effort focused on policy, advocacy, and practical implementation.

Company

About OraSure Technologies, Inc.

OraSure Technologies Inc. is a medical diagnostics and sample management company focused on point-of-need and home testing solutions. OraSure Technologies Inc. develops, manufactures, markets, and distributes rapid diagnostic tests, oral fluid collection devices, and specimen management products used in infectious disease screening, drug testing, and molecular research. Its portfolio includes products for HIV, hepatitis C, syphilis, and respiratory testing, along with sample collection and stabilization kits that support genomics, microbiome, and other life science workflows. The company serves clinical laboratories, hospitals, public health organizations, physicians, researchers, and other professional markets, playing a role in expanding access to easier specimen collection and diagnostic information.

CEO Ms. Carrie Eglinton Manner · 500 employees · United States · https://www.orasure.com